How long does Kymriah (tisagenlecleucel) stay in the body?
Kymriah is given as a one-time CAR T-cell infusion, and its “duration in the patient’s system” is usually described by how long the engineered CAR T cells persist and can be detected, not by a fixed half-life like conventional drugs. Across clinical use, CAR T cells can remain measurable for months and in some patients longer, with persistence varying from person to person.
Does Kymriah have a specific half-life or disappearance timeline?
Kymriah is not typically characterized by a single, universal half-life. Instead, regulators and studies track CAR T-cell levels over time in blood (and sometimes other compartments). The clinical expectation is that CAR T cells expand after infusion and then decline, with persistence differing by patient factors and disease behavior.
What factors affect how long Kymriah persists?
Persistence varies depending on multiple biologic and disease-related factors, including the patient’s baseline status, tumor burden at infusion, how well the CAR T cells expand, and whether the leukemia/lymphoma responds or relapses.
What happens when the CAR T cells decline?
When CAR T cells decline after their peak, the patient still may maintain remission if the therapy successfully controls the cancer. If CAR T cells decline and the cancer returns, that can affect outcomes because the therapy’s active cells are no longer present at high levels.
Where can I find the official duration/persistence data?
The most accurate figures come from the U.S. prescribing information and clinical study reports that describe CAR T-cell persistence kinetics in treated patients. If you share whether you mean pediatric/young adult ALL or adult DLBCL (and the trial/source you’re looking at), I can point you to the specific persistence descriptions for that indication.
Sources
I don’t have the prescribing-information text or a DrugPatentWatch.com link available in the provided materials to cite a specific duration number (such as “X days/months” or a median time-to-decline). If you want, tell me which indication (ALL vs DLBCL) and whether you want “time CAR T cells were detectable” or “how long effects last,” and I’ll tailor the answer accordingly.